Palladium-Catalyzed Mono-α-arylation of Carbonyl-Containing Compounds with Aryl Halides using DalPhos Ligands
作者:Sarah M. Crawford、Pamela G. Alsabeh、Mark Stradiotto
DOI:10.1002/ejoc.201200951
日期:2012.10
We report the extension and optimization of the [Pd(cinnamyl)Cl]2/DalPhos catalyst system, previously found effective for the mono-α-arylation of acetone, to the mono-α-arylation of a variety of carbonyl-containing compounds with aryl halides and heteroaryl halides. Aryl methyl ketones, heteroaryl methyl ketones, propiophenones, malonates, and methoxyacetone can be α-arylated under relatively mild
Deoxybenzoins from Stille carbonylative cross-couplings using molybdenum hexacarbonyl
作者:Jonas Sävmarker、Jonas Lindh、Peter Nilsson
DOI:10.1016/j.tetlet.2010.10.115
日期:2010.12
Stille-type carbonylative cross-couplings, employing palladium catalysis and Mo(CO)6 as the carbonmonoxide carrier, were used for the preparation of deoxybenzoins. Straightforward transformations were conveniently performed in closed vessels at 100 °C, providing the products in good yields. Benzyl bromides and chlorides were used as coupling partners with aryl and heteroaryl stannanes. This mild three-component
[EN] 4, 5-DIHYDRO-LH-IMIDAZOL-2-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF RESPIRATORY, CARDIOVASCULAR, NEUROLOGICAL OR GASTROINTESTINAL DISORDERS<br/>[FR] DERIVES DE 4,5-DIHYDRO-LH-IMIDAZOL-2-AMINE DESTINES A ETRE UTILISES DANS LE TRAITEMENT DES TROUBLES RESPIRATOIRES, CARDIO-VASCULAIRES, NEUROLOGIQUES OU GASTRO-INTESTINAUX
申请人:ALBIREO AB
公开号:WO2008123821A1
公开(公告)日:2008-10-16
[EN] The present invention relates to new compounds of formula (I), as a free base or salts thereof, to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of compounds of formula (I) and to new intermediates used in the preparation thereof. [FR] L'invention concerne de nouveaux composés de formule (I), une base libre ou des sels de ceux-ci, des compositions pharmaceutiques les contenant, ainsi que l'utilisation thérapeutique de ces composés. L'invention concerne également des procédés de préparation des composés de formule (I), ainsi que de nouveaux intermédiaires utilisés dans la préparation de ces composés.